An ultrasound contrast agent targeted to P-selectin detects activated platelets at supra-arterial shear flow conditions

Investigative Radiology

Volumn 45, Issue 10, 2010, Pages 586-591

  Guenther, Felix ^a   Von Zur Muhlen, Constantin ^a   Ferrante, Elisa A ^b   Grundmann, Sebastian ^a   Bode, Christoph ^a   Klibanov, Alexander L ^b,c,d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF VIRGINIA   (United States)

^c University of Virginia   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

activated platelets; P selectin; targeted microbubbles; ultrasound contrast

Indexed keywords

ADENOSINE DIPHOSPHATE; BIOTIN; ECHO CONTRAST MEDIUM; LIGAND; PADGEM PROTEIN; POLYACRYLAMIDE; POLYMER; RECOMBINANT PROTEIN; SIALYL LEWIS X ANTIGEN; STREPTAVIDIN;

ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; BIOTINYLATION; CELL CULTURE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; HUMAN; HUMAN CELL; MICROBUBBLE; PRIORITY JOURNAL; SHEAR RATE; SHEAR STRESS; THROMBOCYTE; THROMBOCYTE ACTIVATION; ULTRASOUND;

EID: 77957259579     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181ed1b3b     Document Type: Article

References (53)

1. Von Zur Muhlen C, von Elverfeldt D, Moeller JA, et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation. 2008; 118:258-267.
2. Massberg S, Brand K, Gruner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002;196:887-896.
3. Corti R, Farkouh ME, Badimon JJ. The vulnerable plaque and acute coronary syndromes. Am J Med. 2002;113:668-680.
4. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115:3378-3384.
5. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol. 1995; 15:1512-1531.
6. Matter CM, Stuber M, Nahrendorf M. Imaging of the unstable plaque: how far have we got? Eur Heart J. 2009;30:2566-2574.
7. Langer HF, Haubner R, Pichler BJ, et al. Radionuclide imaging: a molecular key to the atherosclerotic plaque. J Am Coll Cardiol. 2008;52:1-12.
8. Skajaa T, Cormode DP, Falk E, et al. High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:169-176.
9. Bazeli R, Coutard M, Daumas-Duport B, et al. In vivo evaluation of a new MRI contrast agent (p947) to target matrix metalloproteinases in expanding experimental abdominal aortic aneurysms. Invest Radiol. 2010;45:662-668.
10. Corot C, Petry KG, Trivedi R, et al. Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultra small superparamag-netic iron oxide in magnetic resonance imaging. Invest Radiol. 2004;39:619-625.
11. Li ZY, Tang T, U-King-Im J, et al. Assessment of carotid plaque vulnerability using structural and geometrical determinants. Circ J. 2008;72:1092-1099.
12. von Zur Muhlen C, von Elverfeldt D, Choudhury RP, et al. Functionalized magnetic resonance contrast agent selectively binds to glycoprotein IIb/IIIa on activated human platelets under flow conditions and is detectable at clinically relevant field strengths. Mol Imaging. 2008;7:59-67.
13. Amirbekian V, Lipinski MJ, Briley-Saebo KC, et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci USA. 2007;104:961-966.
14. Briley-Saebo KC, Mulder WJ, Mani V, et al. Magnetic resonance imaging of vulnerable atherosclerotic plaques: current imaging strategies and molecular imaging probes. J Magn Reson Imaging. 2007;26:460-479.
15. Burgstahler C, Hombach V, Rasche V. Molecular imaging of vulnerable plaque by cardiac magnetic resonance imaging. Semin Thromb Hemost. 2007;33:165-172. (Pubitemid 46427759)
16. Burtea C, Laurent S, Murariu O, et al. Molecular imaging of alpha v beta3 integrin expression in atherosclerotic plaques with a mimetic of RGD peptide grafted to Gd-DTPA. Cardiovasc Res. 2008;78:148-157.
17. Burtea C, Laurent S, Port M, et al. Magnetic resonance molecular imaging of vascular cell adhesion molecule-1 expression in inflammatory lesions using a peptide-vectorized paramagnetic imaging probe. J Med Chem. 2009;52:4725-4742.
18. Flacke S, Fischer S, Scott MJ, et al. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation. 2001;104:1280-1285.
19. Laufer EM, Winkens MH, Narula J, et al. Molecular imaging of macrophage cell death for the assessment of plaque vulnerability. Arterioscler Thromb Vasc Biol. 2009;29:1031-1038.
20. Vymazal J, Spuentrup E, Cardenas Molina G, et al. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility. Invest Radiol. 2009;44:697-704.
21. Wilensky RL, Song HK, Ferrari VA. Role of magnetic resonance and intravascular magnetic resonance in the detection of vulnerable plaques. J Am Coll Cardiol. 2006;47:C48-C56.
22. Zheng J, Ochoa E, Misselwitz B, et al. Targeted contrast agent helps to monitor advanced plaque during progression: a magnetic resonance imaging study in rabbits. Invest Radiol. 2008;43:49-55.
23. Takalkar AM, Klibanov AL, Rychak JJ, et al. Binding and detachment dynamics of microbubbles targeted to P-selectin under controlled shear flow. J Control Release. 2004;96:473-482.
24. Klibanov AL. Ultrasound molecular imaging with targeted microbubble contrast agents. J Nucl Cardiol. 2007;14:876-884.
25. Klibanov AL, Rychak JJ, Yang WC, et al. Targeted ultrasound contrast agent for molecular imaging of inflammation in high-shear flow. Contrast Media Mol Imaging. 2006;1:259-266.
26. Rychak JJ, Li B, Acton ST, et al. Selectin ligands promote ultrasound contrast agent adhesion under shear flow. Mol Pharm. 2006;3:516-524.
27. Klibanov AL. Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Invest Radiol. 2006;41:354-362.
28. Dayton P, Klibanov A, Brandenburger G, et al. Acoustic radiation force in vivo: a mechanism to assist targeting of microbubbles. Ultrasound Med Biol. 1999;25:1195-1201.
29. Rychak JJ, Lindner JR, Ley K, et al. Deformable gas-filled microbubbles targeted to P-selectin. J Control Release. 2006;114:288-299.
30. Kobzdej MM, Leppanen A, Ramachandran V, et al. Discordant expression of selectin ligands and sialyl Lewis x-related epitopes on murine myeloid cells. Blood. 2002;100:4485-4494.
31. Ley K. Molecular mechanisms of leukocyte recruitment in the inflammatory process. Cardiovasc Res. 1996;32:733-742.
32. McEver RP. Role of selectins in leukocyte adhesion to platelets and endothelium. Ann NY Acad Sci. 1994;714:185-189.
33. Gawaz M, Neumann FJ, Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation. 1999;99:E1-E11.
34. White J. Anatomy and Structural Organization of the Platelet. 2nd ed. Philadelphia, PA: JB Lippincott Co; 1994.
35. Stehbens WE. The role of hemodynamics in the pathogenesis of atherosclerosis. Prog Cardiovasc Dis. 1975;18:89-103.
36. Zarins CK, Bomberger RA, Glagov S. Local effects of stenoses: increased flow velocity inhibits atherogenesis. Circulation. 1981;64:II221-II227.
37. Alonso A, Della Martina A, Stroick M, et al. Molecular imaging of human thrombus with novel abciximab immunobubbles and ultrasound. Stroke. 2007;38:1508-1514.
38. Martin MJ, Chung EM, Goodall AH, et al. Enhanced detection of thrombo-emboli with the use of targeted microbubbles. Stroke. 2007;38:2726-2732.
39. Schumann PA, Christiansen JP, Quigley RM, et al. Targeted-microbubble binding selectively to GPIIb IIIa receptors of platelet thrombi. Invest Radiol. 2002;37:587-593.
40. Ferrante EA, Pickard JE, Rychak J, et al. Dual targeting improves micro-bubble contrast agent adhesion to VCAM-1 and P-selectin under flow. J Control Release. 2009;140:100-107.
41. Sakamoto S, Watanabe T, Tokumaru T, et al. Expression of Lewisa, Lewisb, Lewisx, Lewisy, siayl-Lewisa, and sialyl-Lewisx blood group antigens in human gastric carcinoma and in normal gastric tissue. Cancer Res. 1989;49: 745-752
42. Ugorski M, Laskowska A. Sialyl Lewis(a): a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochim Pol. 2002;49:303-311.
43. Green PJ, Tamatani T, Watanabe T, et al. High affinity binding of the leucocyte adhesion molecule L-selectin to 3'-sulphated-Le (a) and-Le (x) oligosaccharides and the predominance of sulphate in this interaction demonstrated by binding studies with a series of lipid-linked oligosaccharides. Biochem Biophys Res Commun. 1992;188:244-251.
44. Greenberg AW, Brunk DK, Hammer DA. Cell-free rolling mediated by L-selectin and sialyl Lewis(x) reveals the shear threshold effect. Biophys J. 2000;79:2391-2402.
45. Nelson RM, Dolich S, Aruffo A, et al. Higher-affinity oligosaccharide ligands for E-selectin. J Clin Invest. 1993;91:1157-1166.
46. Revelle BM, Scott D, Kogan TP, et al. Structure-function analysis of P-selectin-sialyl LewisX binding interactions. Mutagenic alteration of ligand binding specificity. J Biol Chem. 1996;271:4289-4297.
47. Varki A. Selectin ligands. Proc Natl Acad Sci USA. 1994;91:7390-7397.
48. Weitz-Schmidt G, Stokmaier D, Scheel G, et al. An E-selectin binding assay based on a polyacrylamide-type glycoconjugate. Anal Biochem. 1996;238: 184-190.
49. Zhang X, Bogorin DF, Moy VT. Molecular basis of the dynamic strength of the sialyl Lewis X-selectin interaction. Chemphyschem. 2004;5:175-182.
50. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008;451:953-957.
51. Wu JC, Bengel FM, Gambhir SS. Cardiovascular molecular imaging. Radiology. 2007;244:337-355.
52. Weller GE, Villanueva FS, Tom EM, et al. Targeted ultrasound contrast agents: in vitro assessment of endothelial dysfunction and multi-targeting to ICAM-1 and sialyl Lewisx. Biotechnol Bioeng. 2005;92:780-788.
53. Klibanov AL, Hughes MS, Villanueva FS, et al. Targeting and ultrasound imaging of microbubble-based contrast agents. MAGMA. 1999;8:177-184.